Bangalore News Network
Advertise With BNN
About Us
Bangalore News Network
BNN
Karnataka Elections 2018
Industry & Commerce
Launches
Health
Social Service
Sports
Politics
Fashion & Entertainment
Interviews
Other News
Feedback
Trending News
List All News
Request News Coverage

Collaboration between Atelerix Ltd (UK) and LV Prasad Eye Institute (India) to treat corneal blindness

The companies have agreed outline commercial terms for the treatment, once it is approved by the regulatory authorities, and a successful launch made, it could result in the restoration of sight for thousands of people. From the purely commercial perspective, this collaborative venture could generate up to £2-3M per year for the UK-based company, depending on the successful uptake of the treatment across Asia, and lead to the creation of up to 10 new jobs at its laboratories in the north-east of England
Bengaluru | Written by: BNN Team | Updated: 05-05-2018 | Views: 103
TRENDING
Launches - Alliance Tire Group (ATG) Launches a Ne ...
Others - Jain (Deemed-to-be University) and Aptec ...
Others - Shangri-La Hotel, Bengaluru appoints ne ...

Atelerixa UK-based start-up company that has developed a method for transporting human cells at room temperature by encapsulating them in an alginate gel has collaborated with The LV Prasad Eye Institute (LVPEI). 


Atelerix is a spin-out from Newcastle University in the UK, is commercialising the transformative technology for the storage and transport of viable cells, including stem cells, for a wide range of uses in human healthcare.It overcomes the problems presented by the current need for cryo-shipping as it is simple, cell-friendly and user-friendly, and offers immediate access to cell therapies.


The LV Prasad Eye Institute (LVPEI) is the largest eye carenetwork in India. It is a not-for-profit, comprehensive eye care institution committed to delivering high-quality treatment and care for patients, embracing all socio-economic backgrounds. Their motto is “So that all may see” and in evidence of this they have treated 24 million people over the last 30 years, with more than half the services provided free of cost, regardless of complexity. 


There are approximately 130,000 people suffering from corneal blindness in India with some 30,000 new cases every year. About 30% of the time both eyes are damaged simultaneously and 40% of the injuriesoccur in children. The standard of care is to perform a corneal transplant, but although the surgery is quick and straightforward, it ishigh maintenance treatment with immunosuppressant eyedrops being required daily for life, with patient compliance beingpoor.


LVPEI are developing a stem cell treatment for reversal of the scarring, and have beenseeing very encouraging results from their clinical trials. At present, however, they can only treat patients in Hyderabad where the clinic is physically situated close to the eye bank from which they isolate the cells and culture the cells in their cGMP facility. As things stand, the shelf life of those isolated cells is 6-8 hours making it impossible to transport the cells to their other regional centres across India or to their multiple smaller centres that would otherwise carry out the procedure.


Earlier this year,the Atelerix team won a grant from the DIT and travelled to Hyderabad to work in the labs of LVPEI to show that their technology can extend the shelf life of the cells to 5 days - a massive change over the current standard and potentially making the treatment available across the whole of India and beyond.


Commenting on the tie up, Professor CheConnon, Professor of Tissue Engineering at Newcastle University, U.K and the Scientific founder of Atelerix said: “It’s really exciting for me to see science developed in my tissue engineering lab at Newcastle University be translated into the clinic. The fact that our work could eventually help millions of people regain their sight is incredibly rewarding. And this is only the beginning of potential application of this technology. It is certainly not limited to cell therapy of the eye and we could see it being employed across many other modern treatments.”
 

COMPANY
About Us
Promoters
Advertise With Us
Careers
Feedback / Contact Us
NEWS SECTIONS
Industry & Commerce
Fashion & Entertainment
Health
Politics
Sports
POLICIES
Copyright Policy
Terms of Use
Privacy Policy
Complaints
CONTACT INFORMATION
Bangalore News Network
General:
info@bangalorenewsnetwork.com
Complaints:
Complaints@bangalorenewsnetwork.com
Send Your Feedback Here
Copyright © 2003 Bangalore News Network.
Software by Probiz IT & ITES